Search Result

Results for "

thromboxane synthase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PGE synthase (3) Calcium Channel (1) COX (2) Endogenous Metabolite (1) Lipoxygenase (2) Prostaglandin Receptor (34) Reference Standards (5)
By Research Areas:	Cancer (2) Cardiovascular Disease (29) Endocrinology (3) Infection (1) Inflammation/Immunology (12) Metabolic Disease (1) Neurological Disease (6)

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Antibodies

Targets Recommended: PGE synthase Acetolactate Synthase (ALS) Thymidylate Synthase Cellulose Synthase ATP Synthase GSK-3 Fatty Acid Synthase (FASN) Glucosylceramide Synthase (GCS) Cyclic GMP-AMP Synthase NO Synthase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0428

Ozagrel 1 Publications Verification OKY-046	Prostaglandin Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Ozagrel (OKY-046) is a high selective and orally active thromboxane A₂ (TXA₂) synthase inhibitor with an IC₅₀ of 11 nM. Ozagrel exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of TXA₂ and increasing the production of prostacyclin (PGI2). Ozagrel can be used for the study of ischemic stroke, asthma and thromboembolic diseases .

HY-A0221

Ridogrel R 68070	Prostaglandin Receptor	Inflammation/Immunology
Ridogrel (R 68070) is an orally active combined thromboxane A2 synthetase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor blocker. Ridogrel is potent antiplatelet agent. Anti-inflammatory activities .

HY-106961

ONO 1301 ONO-AP 500-02	Prostaglandin Receptor	Cardiovascular Disease
ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting prostacyclin agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig .

HY-B0428B

Ozagrel hydrochloride 1 Publications Verification OKY-046 hydrochloride	Prostaglandin Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Ozagrel hydrochloride (OKY-046 hydrochloride) is a high selective and orally active thromboxane A₂ (TXA₂) synthase inhibitor with an IC₅₀ of 11 nM. Ozagrel hydrochloride exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of TXA₂ and increasing the production of prostacyclin (PGI2). Ozagrel hydrochloride can be used for the study of ischemic stroke, asthma and thromboembolic diseases .

HY-106961A

(Z)-ONO 1301 (Z)-ONO-AP 500-02	Prostaglandin Receptor	Cardiovascular Disease
(Z)-ONO 1301 is the isomer of ONO 1301 (HY-106961), and can be used as an experimental control. ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting prostacyclin agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig .

HY-141469

6,9,12,15,18-Heneicosapentaenoic acid HPA; Heneicosapentaenoic acid methyl ester	PGE synthase Lipoxygenase	Cardiovascular Disease Neurological Disease
6,9,12,15,18-Heneicosapentaenoic acid (HPA) is a ∆5 desaturase inhibitor. 6,9,12,15,18-Heneicosapentaenoic acid serves as a weak substrate for Prostaglandin H synthase and 5-lipoxygenase, yet it inactivates Prostaglandin H synthase at a rate comparable to that of AA, EPA and DHA. 6,9,12,15,18-Heneicosapentaenoic acid is a weak inducer of Aacyl-CoA oxidase. 6,9,12,15,18-Heneicosapentaenoic acid incorporates into phospholipids and triacylglycerols in cell culture. 6,9,12,15,18-Heneicosapentaenoic acid can be used in research related to liver cancer .

HY-106067A

Dazoxiben hydrochloride UK 37248	Prostaglandin Receptor	Inflammation/Immunology
Dazoxiben hydrochloride is a potent and orally active **thromboxane (TX) synthase** inhibitor .

HY-B0428A

Ozagrel sodium 1 Publications Verification OKY-046 sodium	Prostaglandin Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Ozagrel sodium (OKY-046 sodium) is a high selective and orally active thromboxane A₂ (TXA₂) synthase inhibitor with an IC₅₀ of 11 nM. Ozagrel sodium exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of TXA₂ and increasing the production of prostacyclin (PGI2). Ozagrel sodium can be used for the study of ischemic stroke, asthma and thromboembolic diseases .

HY-B1735

Picotamide	Prostaglandin Receptor	Cardiovascular Disease
Picotamide is a combined inhibitor of thromboxane A2 (TxA2) synthase and receptor. Picotamide has antiplatelet activity. Picotamide promotes the reduction of microalbuminuria and the inhibition of growth of carotid plaques in diabetes. Picotamide can be used for researching acute or chronic cardiovascular diseases .

HY-113445

Thromboxane B3	COX Endogenous Metabolite	Endocrinology
Thromboxane B3 is a prostaglandin analog derived from arachidonic acid (AA) in the cyclooxygenase (COX) metabolic pathway. Thromboxane B3 is generated from arachidonic acid (AA) in platelets and vascular endothelial cells through the catalysis of cyclooxygenase (COX) and thromboxane synthase (TXS). Thromboxane B3 has been reported to be formed by human platelets upon ingestion of eicosapentaenoic acid (C20: 5ω3) .

HY-135447

BM-531	Prostaglandin Receptor	Others
BM-531 is a dual-acting agent for thromboxane receptor (TXA2) antagonism and thromboxane synthase inhibition. BM-531 exerts anti-aggregatory effects on human citrated platelet-rich plasma (PRP), inhibiting Arachidonic acid (HY-109590A)-induced aggregation with an ED₁₀₀ of 0.125 μM and U-46619 (HY-108566)-induced aggregation with an ED₅₀ of 0.482 μM. BM-531 inhibits high-K ⁺-induced contraction of porcine uterine smooth muscle .

HY-105193

E 3040	Lipoxygenase Prostaglandin Receptor	Inflammation/Immunology
E 3040 is an orally active dual inhibitor of 5-lipoxygenase and **thromboxane synthase**. E 3040 exhibits anti-inflammatory effect .

HY-165587

BM-573	Prostaglandin Receptor	Cardiovascular Disease
BM-573 is an orally active dual thromboxane A₂ (TXA₂) modulator with an IC₅₀ of 1.3 nM. BM-573 possesses both thromboxane synthase (TxAS) inhibition and thromboxane receptor (TP) antagonistic effects. BM-573 can completely inhibit platelet aggregation induced by Arachidonic acid (HY-109590) or U-46619 (TXA₂ analogues). BM-573 completely blocks the generation of TXB₂ (the stable metabolite of TXA₂) in human platelets and does not inhibit cyclooxygenase (COX-1/COX-2), thus avoiding interference with other prostaglandin synthesis. BM-573 has an inhibitory effect on U-46619-induced contractions in rat gastric fundus smooth muscle (ED₅₀ = 4.2 μM), but has no effect on contractions caused by PGE₂, PGF₂α, or PGI₂. BM-573 can be used in the study of atherosclerosis, myocardial infarction, pulmonary hypertension and shock .

HY-19189

Terbogrel BIBV 308SE	Prostaglandin Receptor	Cardiovascular Disease Endocrinology
Terbogrel is an orally available thromboxane A2 receptor antagonist and a **thromboxane A2 synthase inhibitor, with both IC₅₀**s of about 10 nM.

HY-19132

CGS-22652	Prostaglandin Receptor	Cardiovascular Disease
CGS 22652 is a potent thromboxane A2 receptor antagonist. CGS 22652 has selective **thromboxane A2 synthase** inhibitory properties. CGS 22652 can be used in the research of coronary artery thrombosis .

HY-105866

Wy 27569	Calcium Channel Prostaglandin Receptor	Cardiovascular Disease
Wy 27569 is an orally active vascular selective calcium channel blocker that can effectively lower blood pressure. Wy 27569 is a thromboxane synthase inhibitor that can reshape prostaglandin balance, reduce pro thrombotic TXA2, and increase anti thrombotic PGI2. Wy 27569 can be used for research on cardiovascular diseases such as hypertension and angina .

HY-129786

LG 82-4-00	Prostaglandin Receptor	Cardiovascular Disease
LG 82-4-00 is a **thromboxane (TX) synthase inhibitor with an IC₅₀ value of 1.1 μM. LG 82-4-00 can inhibit collagen-induced TXB₂** formation and platelet aggregation in plasma. LG 82-4-00 can be used in studies related to thrombotic diseases .

HY-106080A

Furegrelate sodium U-63557A	Prostaglandin Receptor	Cardiovascular Disease
Furegrelate Sodium (U-63557A) is a potent, orally available, and selective **thromboxane synthase** inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC₅₀ of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent .

HY-106080

Furegrelate U-63557A free acid	Prostaglandin Receptor	Cardiovascular Disease
Furegrelate (U-63557A free acid) is a potent, orally available, and selective **thromboxane synthase** inhibitor. Furegrelate inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC₅₀ of 15 nM. Furegrelate is being developed as an antiplatelet agent .

HY-105114

Imitrodast	Prostaglandin Receptor	Inflammation/Immunology
Imitrodast is an inhibitor of thromboxane synthase. Imitrodast can be used in the research of bronchoconstriction .

HY-106080AR

Furegrelate sodium (Standard) U-63557A (Standard)	Prostaglandin Receptor Reference Standards	Cardiovascular Disease
Furegrelate (sodium) (Standard) is the analytical standard of Furegrelate (sodium). This product is intended for research and analytical applications. Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent .

HY-106119

Camonagrel	Prostaglandin Receptor	Infection
Camonagrel is a compound that has inhibitory effects on Prostaglandin E2. Camonagrel is a potent thromboxane synthase inhibitor .

HY-116281

ICI D1542	Prostaglandin Receptor	Cardiovascular Disease
ICI D1542 is a selective and potent inhibitor of **thromboxane A2 (TXA2) synthase** and the thromboxane A2 receptor (TP-receptor). ICI D1542 is effective at preventing thrombus formation by redirection of arachidonic acid metabolism .

HY-124150

BM567	Prostaglandin Receptor	Cardiovascular Disease
BM567 is a sulfonylurea compound (compound 1), which exhibits antithrombogenic efficacy as thromboxane A₂ receptor (TXR) antagonists and thromboxane A₂ synthase (TXS) inhibitors, with IC₅₀s of 1.1 and 12 nM, respectively .

HY-118765

Ro 23-3423	Prostaglandin Receptor	Cardiovascular Disease
Ro 23-3423 is a thromboxane synthase inhibitor with an IC₅₀ value of 0.33 μM for human platelet microsomal thromboxane synthase. Ro 23-3423 increases plasma levels of PGF and PGE2 in a dose-dependent manner, accompanied by a decrease in mean systemic arterial pressure and systemic vascular resistance. Ro 23-3423 can be used in the study of general anesthesia .

HY-117019

LY150310 free base	COX	Cancer
LY150310 inhibits thromboxane synthase, cyclooxygenase, and thrombin activation. LY150310 inhibits spontaneous lung metastasis in a dose-dependent manner.

HY-U00231

KF 13218	Prostaglandin Receptor	Cardiovascular Disease Endocrinology
KF 13218 is a potent, selective and long lasting thromboxane B2 (TXB2) synthase inhibitor with an IC₅₀ value of 5.3±1.3 nM.

HY-119890

Isbogrel CV-4151	Prostaglandin Receptor	Cardiovascular Disease Cancer
Isbogrel (CV-4151) is a potent selective inhibitor of thromboxane A2 synthase. Isbogrel has oral activity and inhibits blood TXA2 generation with an ID₅₀ value of 0.04 mg/kg .

HY-129199

U-51605	PGE synthase	Cardiovascular Disease
U-51605 is a platelet aggregation inhibitor and inhibits thromboxane synthesis. U-51605 is also a prostaglandin I2 synthase inhibitor and can inhibit the retinal vasodilation response induced by NO donors (such as NOR3) .

HY-122178

5-trans U-44069	PGE synthase	Cardiovascular Disease
5-trans U-44069 is the trans isomer of the thromboxane receptor agonist U-44069 (HY-121825). 5-trans U-44069 inhibits prostaglandin E2 synthase activity .

HY-137227

15(R)-PTA2 15(R)-Pinanethromboxane A2	Prostaglandin Receptor	Cardiovascular Disease
15(R)-PTA2 (15(R)-Pinanethromboxane A2) is an antithrombotic agent that inhibits platelet aggregation. 15(R)-PTA2 inhibits stable prostaglandin endoperoxide analog-induced constriction of feline coronary arteries and stabilizes hepatic lysosomes. 15(R)-PTA2 also inhibits thromboxane synthase but has no effect on prostacyclin synthase .

HY-B0428BR

Ozagrel hydrochloride (Standard) OKY-046 hydrochloride (Standard)	Reference Standards Prostaglandin Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Ozagrel hydrochloride (Standard) is the analytical reference standard of Ozagrel hydrochloride (HY-B0428B). Ozagrel hydrochloride (OKY-046 hydrochloride) is a high selective and orally active thromboxane A₂ (TXA₂) synthase inhibitor with an IC₅₀ of 11 nM. Ozagrel hydrochloride exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of TXA₂ and increasing the production of prostacyclin (PGI2). Ozagrel hydrochloride can be used for the study of ischemic stroke, asthma and thromboembolic diseases .

HY-105114A

Imitrodast sodium CS-518	Prostaglandin Receptor	Inflammation/Immunology
Imitrodast sodium is an inhibitor of **thromboxane synthase**. Imitrodast sodium can be used in the research of bronchoconstriction .

HY-105265

Rolafagrel FCE 22178	Prostaglandin Receptor	Cardiovascular Disease
Rolafagrel is an inhibitor of **thromboxane synthase**. Rolafagrel can be studied in cardiovascular research .

HY-106398

MED 27	Prostaglandin Receptor	Cardiovascular Disease
MED 27 is an inhibitor of **thromboxane synthase** and thromboxane A2 receptors. MED 27 can inhibit rat platelet aggregation at doses much lower than that of Acetylsalicylic acid (HY-14654) .

HY-106067AR

Dazoxiben hydrochloride (Standard) UK 37248 (Standard)	Reference Standards Others	Inflammation/Immunology
Dazoxiben (hydrochloride) (Standard) is the analytical standard of Dazoxiben (hydrochloride). This product is intended for research and analytical applications. Dazoxiben hydrochloride is a potent and orally active thromboxane (TX) synthase inhibitor .

HY-A0221R

Ridogrel (Standard) R 68070 (Standard)	Prostaglandin Receptor Reference Standards	Inflammation/Immunology
Ridogrel (Standard) is the analytical standard of Ridogrel. This product is intended for research and analytical applications. Ridogrel (R 68070) is an orally active combined thromboxane A2 synthetase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor blocker. Ridogrel is potent antiplatelet agent. Anti-inflammatory activities .

HY-B1735A

Picotamide monohydrate	Prostaglandin Receptor	Cardiovascular Disease Metabolic Disease
Picotamide monohydrate is a combined inhibitor of thromboxane A2 (TxA2) synthase and receptor. Picotamide monohydrate has antiplatelet activity. Picotamide monohydrate promotes the reduction of microalbuminuria and the inhibition of growth of carotid plaques in diabetes. Picotamide monohydrate can be used for researching acute or chronic cardiovascular diseases .

HY-106961R

ONO 1301 (Standard) ONO-AP 500-02 (Standard)	Reference Standards Prostaglandin Receptor	Cardiovascular Disease
ONO 1301 (Standard) (ONO-AP 500-02 (Standard)) is the analytical standard of ONO 1301 (HY-106961). This product is intended for research and analytical applications. ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting prostacyclin agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig .

HY-B0428D

(E/Z)-Ozagrel sodium (E/Z)-OKY-046 sodium	Prostaglandin Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
(E/Z)-Ozagrel sodium [(E/Z)-OKY-046 sodium] is an EZ configuration mixture of Ozagrel sodium (HY-B0428A). Ozagrel sodium (OKY-046 sodium) is a high selective and orally active thromboxane A₂ (TXA₂) synthase inhibitor with an IC₅₀ of 11 nM. Ozagrel sodium exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of TXA₂ and increasing the production of prostacyclin (PGI2). Ozagrel sodium can be used for the study of ischemic stroke, asthma and thromboembolic diseases .

Cat. No.	Product Name	Type

HY-135447

BM-531	Biochemical Assay Reagents
BM-531 is a dual-acting agent for thromboxane receptor (TXA2) antagonism and thromboxane synthase inhibition. BM-531 exerts anti-aggregatory effects on human citrated platelet-rich plasma (PRP), inhibiting Arachidonic acid (HY-109590A)-induced aggregation with an ED₁₀₀ of 0.125 μM and U-46619 (HY-108566)-induced aggregation with an ED₅₀ of 0.482 μM. BM-531 inhibits high-K ⁺-induced contraction of porcine uterine smooth muscle .

BM-531

Biochemical Assay Reagents

BM-531 is a dual-acting agent for thromboxane receptor (TXA2) antagonism and thromboxane synthase inhibition. BM-531 exerts anti-aggregatory effects on human citrated platelet-rich plasma (PRP), inhibiting Arachidonic acid (HY-109590A)-induced aggregation with an ED₁₀₀ of 0.125 μM and U-46619 (HY-108566)-induced aggregation with an ED₅₀ of 0.482 μM. BM-531 inhibits high-K ⁺-induced contraction of porcine uterine smooth muscle .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-141469

6,9,12,15,18-Heneicosapentaenoic acid HPA; Heneicosapentaenoic acid methyl ester	Structural Classification Animals Lipid Source Classification	PGE synthase Lipoxygenase
6,9,12,15,18-Heneicosapentaenoic acid (HPA) is a ∆5 desaturase inhibitor. 6,9,12,15,18-Heneicosapentaenoic acid serves as a weak substrate for Prostaglandin H synthase and 5-lipoxygenase, yet it inactivates Prostaglandin H synthase at a rate comparable to that of AA, EPA and DHA. 6,9,12,15,18-Heneicosapentaenoic acid is a weak inducer of Aacyl-CoA oxidase. 6,9,12,15,18-Heneicosapentaenoic acid incorporates into phospholipids and triacylglycerols in cell culture. 6,9,12,15,18-Heneicosapentaenoic acid can be used in research related to liver cancer .

Host:	Rabbit (2)
Reactivity:	Human (2) Mouse (2)
Application:	IHC-P (1) ICC/IF (1) WB (2)
Isotype:	IgG (2)
Conjugation:	Non-conjugated (2)
Clonality:	Monoclonal (1) Recombinant (1)
Modification:	Unmodified (1)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P82925

	Thromboxane A Synthase Antibody (YA2670) TBXAS1; CYP5; CYP5A1; thromboxane-A synthase; TXA synthase; TXS; Cytochrome P450 5A1	WB	Human, Mouse
	Thromboxane A Synthase Antibody (YA2670) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Thromboxane A Synthase.

HY-P811060

	Cytochrome P450 2S1 Antibody UNQ891/PRO1906, CYP2S1, Cytochrome P450 2S1, CYPIIS1, Hydroperoxy icosatetraenoate dehydratase, thromboxane-A synthase	WB, IHC-P, ICC/IF	Human, Mouse
	Cytochrome P450 2S1 Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to Cytochrome P450 2S1.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

thromboxane synthase

Inhibitors & Agonists

Biochemical Assay Reagents

NaturalProducts

Antibodies

Natural
Products